drugset / Trial / NCT00083915
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if transplant with a new regimen of chemotherapy called DT PACE-Melphalan is better than transplant with Melphalan alone. DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. Another purpose of this study is to find out if there will be fewer side effects with the new regimen of DT PACE-Melphalan, compared to melphalan alone.
Timeline
- Start
- 2001-06
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 20 mg/m2 | — |
| Comparator | Cyclophosphamide | Other / unclassified | 800 mg/m2 | — |
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Doxorubicin | Other / unclassified | 20 mg/m2 | — |
| Comparator | Etoposide | Small molecule | 80 mg/m2 | — |
| Comparator | Melphalan | Small molecule | 50 mg/m2 | Intravenous |
| Comparator | Melphalan | Small molecule | 200 mg/m2 | Intravenous |
| Comparator | Thalidomide | Other / unclassified | 200 mg | Oral |